Lack of correlation of functional scintigraphy with (99m)technetium-methoxyisobutylisonitrile with histological necrosis following induction chemotherapy or measures of P-glycoprotein expression in high-grade osteosarcoma.
暂无分享,去创建一个
S. Larson | E. Calleja | A. Huvos | D. Panicek | J. Healey | S. Yeh | L. Wexler | R. Gorlick | P. Meyers | M. Daras | A. C. Liao | C. Antonescu | R. Sowers
[1] P. D. Lee,et al. MDR1 gene expression and outcome in osteosarcoma: a prospective, multicenter study. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] A. Rastogi,et al. Functional retention of Tc-99m MIBI in mediastinal lymphomas as a predictor of chemotherapeutic response demonstrated by consecutive thoracic SPECT imaging. , 1998, Clinical nuclear medicine.
[3] J. Taki,et al. Assessment of P-glycoprotein in patients with malignant bone and soft-tissue tumors using technetium-99m-MIBI scintigraphy. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[4] T. Grogan,et al. P-glycoprotein expression: critical determinant in the response to osteosarcoma chemotherapy. , 1997, Journal of the National Cancer Institute.
[5] A. Gazdar,et al. Quantitative analysis of MDR1 (multidrug resistance) gene expression in human tumors by polymerase chain reaction. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[6] T. Yen,et al. Technetium‐99m methoxyisobutylisonitrile chest imaging of small cell lung carcinoma , 1998, Cancer.
[7] E. Franssen,et al. 99mTc-sestamibi is a substrate for P-glycoprotein and the multidrug resistance-associated protein. , 1998, British Journal of Cancer.
[8] S. Larson,et al. Thallium‐201 scintigraphy for the evaluation of tumor response to preoperative chemotherapy in patients with osteosarcoma , 1997, Cancer.
[9] T. Kubota,et al. 99mTc-MIBI scintigraphy as an indicator of the chemosensitivity of anthracyclines in patients with breast cancer. , 1998, Anticancer research.
[10] A Ciarmiello,et al. Fractional retention of technetium-99m-sestamibi as an index of P-glycoprotein expression in untreated breast cancer patients. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[11] K. Danenberg,et al. Quantitation of thymidylate synthase, dihydrofolate reductase, and DT-diaphorase gene expression in human tumors using the polymerase chain reaction. , 1992, Cancer research.
[12] Costan,et al. Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations. , 1996, Cancer research.
[13] H. Hollema,et al. 99mTc-Sestamibi scanning with SDZ PSC 833 as a functional detection method for resistance modulation in patients with solid tumours. , 1999, Anticancer research.
[14] A. Huvos,et al. Intensification of preoperative chemotherapy for osteogenic sarcoma: results of the Memorial Sloan-Kettering (T12) protocol. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] S. Jhanwar,et al. Higher levels of thymidylate synthase gene expression are observed in pulmonary as compared with hepatic metastases of colorectal adenocarcinoma. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] F. Atkins,et al. Technetium-99m-sestamibi parathyroid scintigraphy: effect of P-glycoprotein, histology and tumor size on detectability. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[17] G. Rosen,et al. Preoperative chemotherapy for osteogenic sarcoma: Selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy , 1982, Cancer.
[18] H. Bom,et al. Technetium-99m-MIBI uptake in small cell lung cancer. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[19] P. Picci,et al. P‐glycoprotein expression in osteosarcoma: A basis for risk‐adapted adjuvant chemotherapy , 1999, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.
[20] R. Kramer,et al. Functional imaging of multidrug-resistant P-glycoprotein with an organotechnetium complex. , 1993, Cancer research.
[21] T. Fojo,et al. Detection of in vivo P-glycoprotein inhibition by PSC 833 using Tc-99m sestamibi. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.
[22] G Rosen,et al. Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] C. Archer,et al. P-glycoprotein and metallothionein expression and resistance to chemotherapy in osteosarcoma. , 1998, British Journal of Cancer.
[24] P. Picci,et al. Expression of P-glycoprotein in high-grade osteosarcomas in relation to clinical outcome. , 1995, The New England journal of medicine.
[25] H. Hollema,et al. Tc-99m-Sestamibi scanning with SDZ PSC 833 as a functional detection method for resistance modulation in patients with solid tumours , 1999 .
[26] T. Visser,et al. 99mTc-MIBI, 99mTc-tetrofosmin and 99mTc-Q12 in vitro and in vivo. , 1998, Nuclear medicine and biology.
[27] M. Sasaki,et al. Prediction of the chemosensitivity of lung cancer by 99mTc-hexakis-2-methoxyisobutyl isonitrile SPECT. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[28] Y. S. Kim,et al. Tc-99m MIBI SPECT is useful for noninvasively predicting the presence of MDR1 gene-encoded P-glycoprotein in patients with hepatocellular carcinoma. , 1999, Clinical nuclear medicine.
[29] T. Leitha,et al. Is early sestamibi imaging in head and neck cancer affected by MDR status, p53 expression, or cell proliferation? , 1998, Nuclear medicine and biology.
[30] S. Emri,et al. Association of tumor washout rates and accumulation of technetium-99m-MIBI with expression of P-glycoprotein in lung cancer. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[31] A. Huvos,et al. Expression of HER2/erbB-2 correlates with survival in osteosarcoma. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] I. Andrulis,et al. Correlation of p-glycoprotein detection by immunohistochemistry with mdr-1 mRNA levels in osteosarcomas. Pilot study. , 1995, Diagnostic molecular pathology (Print).